Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Releases 2D Gel Electrophoresis Tool

NEW YORK, Sept 19 - Compugen (Nasdaq: CGEN) of Tel Aviv, Israel announced Tuesday the release of Z3, a high-throughput 2 dimensional gel electrophoresis analysis system, marking the company's first foray into the burgeoning proteomics market.

2D gel electrophoresis is the method of choice for separating complex mixtures of proteins, the first step in the typical proteomics research workflow. However, the 2D gel technique is only partially exploited due to difficulties in reproducing the technique and analyzing the results.

Z3 automates the 2D gel analysis process through the use of proprietary algorithms for both gel comparisons and the computation of differential expression, the company said.

Compugen president and CEO Eli Mintz said that Z3 borrows techniques used by other Israeli companies such as Orbotech (Nasdaq: ORBK), which develops optical equipment for inspecting and imaging circuit boards and display panels.

The “technology in under one minute automatically aligns two different pictures,” Mintz said. “One gel is magenta, the other is green. And when you put one on top of the other, the picture becomes black. The computer automatically aligns and registers the pictures at the pixel level and where you see the different colors, you know that’s the difference.”

Once the proteins are extracted, they can be put through a mass spectrometer for analysis.   

The Z3 software system is now commercially available under various licensing arrangements, including a pay-per-gel subscription model, by which gel analysis is consumed similarly to a reagent.

Compugen, which began as a hardware developer, has recently repositioned itself as a proteomics, software, and Web portal company.

Compugen is currently beta-testing the incorporation of a Z3-based 2D gel image analysis service into the company’s Internet-based genomic portal, LabOnWeb.com. Commercial availability of Z3 over LabOnWeb.com is anticipated by the fourth quarter of this year.

The company’s stock was down 11/16, or 4.4 percent, at 15 in afternoon trading.

 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.